Invesaro

Stocks Health care MTNB

NYSE · Health care

Matinas BioPharma Holdings, Inc. (MTNB)

It posted a net loss of $6.7M. At June 30, 2026 it held $761K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price
$0.16
-10.11% on the day · September 25, 2026
52-week range $0.15 to $1.99
Market cap
$2.4M

What Matinas BioPharma Holdings, Inc. does

Matinas BioPharma Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker MTNB.

Revenue and profit by year

Revenue
FY18: $119.8K $119.8K FY18FY19: $89.8K $89.8K FY19FY20: $158.3K $158.3K FY20FY21: $33K $33K FY21FY22: $3.2M $3.2M FY22FY23: $1.1M $1.1M FY23
Net income
FY18: -$14.1M -$14.1M FY18FY19: -$17.4M -$17.4M FY19FY20: -$22.4M -$22.4M FY20FY21: -$23.3M -$23.3M FY21FY22: -$21M -$21M FY22FY23: -$22.9M -$22.9M FY23FY24: -$24.3M -$24.3M FY24FY25: -$10.3M -$10.3M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025n/a-$7M-$10.3M-$2.00n/a
2024n/a-$24.6M-$24.3M-$4.98n/a
2023$1.1M-$23.8M-$22.9M-$5.28-$15.5M
2022$3.2M-$24.6M-$21M-$4.80-$20M
2021$33K-$24.7M-$23.3M-$5.28-$15.5M
2020$158.3K-$24.2M-$22.4M-$5.76-$17.4M

Full financial statements: income, balance sheet and cash flow

Next report expected around November 9, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 10, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Matinas BioPharma Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 16, 2026
  2. September 4, 2026
  3. August 25, 2026
  4. August 13, 2026
    Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.21 versus -$1.03.
  5. August 13, 2026
  6. August 4, 2026
  7. July 30, 2026
  8. July 29, 2026
  9. July 24, 2026
  10. July 21, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 13, 2026. Insider transactions on SEC

Insider trades

What the people running Matinas BioPharma Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
July 10, 2026 Stern Adam K10% owner Exercised optionsindirect 344,710 $0.35 $120.6K Form 4
July 10, 2026 Stern Adam K10% owner Exercised optionsindirect 630,335 $0.35 $220.6K Form 4
October 31, 2025 Stern Adam K10% owner Exercised optionsindirect 92,100 $0.64 $59.4K Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns MTNB

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Stern Adam K13D, may seek influence with 1 related filers 9.99% 2,972,524 August 13, 2026
Hezbay Holdings LLC13G, passive 9.54% 1,306,488 July 14, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 743,785 shares in total, about $119K at the last price.

HolderSharesAs of
Stern Adam K10% owner 743,785743,785 held indirectly July 10, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about MTNB

What does Matinas BioPharma Holdings, Inc. do?

Matinas BioPharma Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker MTNB.

Is Matinas BioPharma Holdings, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $6.7M.

When did Matinas BioPharma Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 16, 2026.

Similar companies

Compare MTNB with

Compare MTNB with any company

Follow MTNB

Get an email when Matinas BioPharma Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow MTNB: get an email when it files

Where the numbers come from

Financial figures are the values Matinas BioPharma Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.